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Abstract. Background: Chronic kidney 
disease (CKD) is associated with acceler-
ated atherosclerosis and an increased risk of 
adverse cardiovascular disease (CVD) out-
comes. The relationships of intima-media 
thickness (IMT), a measure of subclinical 
atherosclerosis, with traditional and non-
traditional risk factors and with adverse 
outcomes in CKD patients are not well-
established. Methods: IMT, clinical char-
acteristics, cardiovascular risk factors, and 
clinical outcomes were measured in 198 
subjects from the Renal Research Institute 
(RRI) CKD study, a four-center prospective 
cohort of patients with estimated glomerular 
filtration rate (eGFR) ≤ 50 mL/min/1.73 m2 
not requiring renal replacement therapy. Re-
sults: The patients averaged 61 ± 14 years 
of age; the mean eGFR was 29 ± 12 mL/
min/1.73 m2. Maximum IMT was more 
closely associated with traditional cardio-
vascular risk factors, including age, diabetes, 
dyslipidemia, and systolic blood pressure, 
than with nontraditional risk factors or with 
eGFR. Higher values of maximum IMT were 
also independently associated with clinical 
CVD and with other markers of subclinical 
CVD. Maximum IMT ≥ 2.6 mm was pre-
dictive of the composite endpoint of CVD 
events and death (hazard ratio (HR): 5.47 
(95% confidence interval (CI): 2.97 – 10.07, 
p < 0.0001)) but was not related to progres-
sion to end-stage renal disease (HR: 1.67 
(95% CI: 0.74 – 3.76, p = 0.21)). Conclusion: 
In patients with advanced pre-dialysis CKD, 
higher maximum IMT was associated with 
traditional cardiovascular risk factors, CVD, 
and other markers of subclinical CVD and 
was an independent predictor of cardiovas-
cular events and death. Additional research is 
needed to examine the clinical utility of IMT 
in the risk stratification and clinical manage-
ment of patients with CKD.
Introduction
Chronic kidney disease (CKD) is as-
sociated with an increased risk of adverse 
cardiovascular disease (CVD) outcomes. In 
patients with kidney failure on dialysis, mor-
tality due to CVD is 10 – 30 times that in the 
general population [1]. Individuals with less-
er degrees of renal dysfunction are also pre-
disposed to cardiovascular events. Several 
recent reports from prospective population-
based studies suggest that mild-to-moderate 
renal insufficiency predicts cardiovascular 
morbidity and mortality [2, 3, 4, 5]. Indeed, 
patients with CKD are more likely to die of 
CVD than to develop renal failure [6, 7, 8].
In patients with CKD there is a high 
prevalence of traditional CVD risk factors, 
such as advanced age, diabetes, and hyper-
tension [9, 10, 11, 12, 13]. Some studies, 
however, indicate that the relationships be-
tween estimated glomerular filtration rate 
(eGFR) and CVD morbidity, and mortality 
are independent of these characteristics [14, 
15, 16]. These observations have led to the 
suggestion that “nontraditional” risk factors, 
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such as inflammation, abnormal calcium and 
phosphorous metabolism, anemia, hyper-
parathyroidism, hypoalbuminemia, and al-
buminuria may contribute to the risk of CVD 
in CKD patients.
Assessment of the intima-media thick-
ness (IMT) of the carotid artery is a repro-
ducible, safe, and non-invasive method of 
detecting subclinical atherosclerosis. Previ-
ous cross-sectional studies in cohorts with-
out CKD have demonstrated associations 
between carotid IMT and both cardiovas-
cular risk factors and the presence of CVD 
[17, 18, 19, 20]. Several large observational 
studies have also shown that carotid IMT is 
a predictor of coronary heart disease events 
that remains significant after adjustment for 
traditional risk factors [21, 22, 23, 24, 25, 
26]. The relationship between IMT and risk 
for cardiovascular events in the context of a 
dominant risk factor such as CKD has been 
examined in only a few studies.
We examined carotid IMT in patients 
with advanced pre-dialysis CKD enrolled 
in the Renal Research Institute (RRI)-CKD 
study to 1) assess the relationships between 
IMT and traditional risk factors, nontradi-
tional risk factors, and other markers of sub-
clinical CVD; and 2) evaluate the relation-
ship of subclinical atherosclerosis to adverse 
clinical outcomes in this population. We 
hypothesized that IMT would be correlated 
with both traditional and nontraditional CVD 
risk factors as well as other markers of car-
diac disease, and would predict both cardio-




The RRI-CKD study is a four-center, 
prospective, observational cohort study in-
volving adult patients with moderate-to-se-
vere CKD, not on dialysis, enrolled between 
06/2000 and 02/2006 (n = 834). Details of 
the study have been described previously 
[27]. Eligibility criteria included age ≥ 18 
years and estimated glomerular filtration rate 
(eGFR) ≤ 50 mL/min by the Cockcroft-Gault 
formula. When enrollment eGFR was recal-
culated by the abbreviated Modification of 
Diet in Renal Disease equation, values were 
greater than 50 mL/min/1.73 m2 in a few 
cases (n = 5). At enrollment and follow-up 
visits, data on demographic characteristics, 
anthropometric measures, cause of CKD, 
symptoms, laboratory values, and medica-
tions were collected.
From January 1, 2003 onwards, a subset 
of individuals from the RRI-CKD cohort 
voluntarily consented to undergo blood, 
urine, and non-invasive cardiovascular stud-
ies, including measurement of carotid IMT. 
In addition, 199 patients were newly re-
cruited into the CVD sub-study. While these 
participants were similar to the original RRI-
CKD cohort participants with respect to age, 
diabetes, hypertension, history of CVD, race, 
gender, and medication use, significantly 
higher mean eGFR (32 vs. 24) was observed. 
Figure 1 displays the patient recruitment 
flow into this analysis. This paper is based 
on patients with carotid IMT data (n = 198).
Patients who enrolled in the cardiovas-
cular sub-study from the original RRI-CKD 
study (n = 149) were generally healthier than 
those who did not; they were younger (mean 
Figure 1. Flow-chart displaying the entry crite-
ria into the cardiovascular sub-study and present 
analysis.
Hinderliter, Padilla, Gillespie, et al. 12
age 58 vs. 64 years), had a higher mean 
eGFR (27 vs. 25 mL/min/1.73 m2), and were 
less likely to have diabetes (30% vs. 42%) 
or a history of CVD (37% vs. 58%). The 
difference between the CVD sub-study and 
RRI-CKD participants was likely due to pa-
tient self-selection into a study that involved 
substantial testing and patient burden. This 
selection seems especially likely because the 
characteristics of the newly recruited CVD 
sub-study patients were similar to the con-
senters from the original RRI-CKD cohort. 
Finally, of the 348 participants enrolled into 
the cardiovascular sub-study, 150 declined 
measurement of IMT. These participants 
were similar to the 198 subjects who under-
went this procedure.
The Institutional Review Boards of the 
participating centers approved the protocol, 
and a written informed consent was obtained 
for all study subjects.
Clinical and laboratory data
Baseline variables collected at the time 
of enrollment in the RRI-CKD study in-
cluded the following: demographic charac-
teristics (e.g., age, sex, and race), clinical 
measurements (e.g., height, weight, blood 
pressure, heart rate), clinical comorbidi-
ties (e.g., diabetes mellitus, hypertension, 
dyslipidemia, and history of tobacco use), 
and laboratory parameters (e.g., serum cre-
atinine, serum calcium, serum phosphorous, 
serum albumin, hematocrit, intact para-
thyroid hormone (iPTH), lipid levels, and 
urine albumin-to-creatinine ratio). Blood 
pressure was measured in duplicate after 5 
minutes of rest in the seated position using 
an automated, oscillometric device (Omron 
model HEM-412C), and the results aver-
aged. Blood specimens were acquired after 
a 12-hour fast. Diabetes was defined as a 
fasting glucose ≥ 126 mg/dL or use of in-
sulin or other medication for glycemic con-
trol. Hypertension was defined by a systolic 
BP ≥ 140 mmHg or use of antihypertensive 
agents. Dyslipidemia was defined as total 
cholesterol ≥ 240 mg/dL, LDL-cholesterol 
≥ 130 mg/dL, HDL-cholesterol ≤ 40 mg/dL, 
or treatment with a statin. Smoking status 
was determined by self-report.
Measures of subclinical 
cardiovascular disease
To insure uniformity of technique, study 
coordinators and sonographers at each site 
were trained in procedures for carotid artery 
ultrasound imaging and other measures of 
subclinical CVD at the University of Michigan 
data coordinating center. Images were ana-




Longitudinal images of the right and left 
common carotid arteries, carotid bulbs, and 
internal carotid arteries were acquired with 
a high-resolution B-mode ultrasound trans-
ducer and recorded for subsequent analy-
sis at the core laboratory. Using electronic 
calipers, IMT was measured as the distance 
between the luminal-intima interface and 
the medial-adventitial interface at multiple 
points of the near and far walls of the distal 
1 cm segments of the common carotid arter-
ies, the carotid bulbs, and the internal carotid 
arteries. The mean IMT was calculated as the 
average of all IMT measurements; the mean 
of maximum IMT was calculated as the av-
erage of maximum wall thickness measure-
ments from each region. The reproducibility 
of IMT measurement in the core laboratory 
has been described in a prior publication [28].
Other measures of subclinical 
cardiovascular disease
Left ventricular mass was calculated 
as described by Devereux et al. [29], from 
echocardiographic measurements of end-
diastolic internal dimension and wall thick-
nesses. Left ventricular mass index (LVMI) 
was derived by correcting left ventricular 
mass for body surface area (LVMI = left 
ventricular mass/body surface area). Arte-
rial stiffness was quantified as the carotid-
femoral pulse wave velocity (PWV) using 
an ATCOR (version 7.0) device, as described 
previously [30]. Coronary calcium was mea-
sured using a 4-slice LightSpeed QXi and 
quantified as the Agatston score using coro-
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nary artery calcium scoring software [31]. 
Flow-mediated dilation of the brachial artery 
(FMD) was assessed by measuring changes 
in arterial diameter induced by reactive hy-
peremia and calculated as the percent change 
in diameter from baseline [32]. Arterial di-
ameters at end-diastole were measured using 
customized software (Brachial Tools, Medi-
cal Imaging Applications, LLC, Coralville 
IA, USA). Measures of heart rate variability 
(HRV) were based on 24-hour ambulatory 
ECG recordings, analyzed using SyneTec 
Holter analysis software, version 1.20 (Ela 
Medical, Paris, France), as described in a 
prior publication [33].
Clinical follow-up
Follow-up of patients ended on Decem-
ber 31, 2006; all 348 patients, except 7 who 
were lost to follow-up, were followed for 
at least 10 months. All outcomes were as-
certained on an ongoing basis by study co-
ordinators, who had no knowledge of IMT 
results, and were based on regular review of 
electronic health records, direct patient con-
tact in clinic, and periodic telephone com-
munication. Endpoints included a composite 
of death or CVD events, including coronary 
events (myocardial infarction, coronary re-
vascularization procedures), cerebrovascular 
events (stroke or transient ischemic attack), 
new onset heart failure, sudden cardiac 
death, or development of peripheral vas-
cular disease requiring revascularization or 
amputation; and progression to end-stage 
renal disease (ESRD), defined as initiation 
of dialysis or pre-emptive renal transplanta-
tion.
Statistical methods
Descriptive data of the study cohort are 
expressed as mean ± standard deviation 
for continuous variables (or median (inter-
quartile range) for skewed variables) and as 
proportions for categorical variables. The 
relationships of IMT with demographic and 
anthropomorphic variables, clinical char-
acteristics, traditional and non-traditional 
coronary risk factors, eGFR, and other mea-
sures of subclinical CVD were assessed by 
Pearson correlations. Multiple linear re-
gressions were performed to assess predic-
tors of carotid IMT, and Cox regression was 
used to analyze time to event outcomes. The 
method of best subsets was used to guide 
model selection process, with the R-squared 
selection criterion used for linear regression 
and the likelihood score (χ2) statistic crite-
rion used for Cox regression [34]. Skewed 
variables were natural log transformed and 
a p-value < 0.05 was considered significant. 
Martingale residuals obtained from Cox re-
gression models were examined to assess 
the correct functional form of IMT (IMT ≥ 
2.6 mm). All analyses were conducted using 
SAS, version 9.2 (SAS Institute Inc., Cary, 
NC USA).
Table 1. Clinical characteristics at the time of non-invasive cardiovascular 
testing in the RRI-CKD cohort for 198 subjects with carotid intima-media thick-
ness measurements.
Mean ±SD or % (n)
Demographic/anthropomorphic measures
 Age (years) 61 (14)
 Body mass index (kg/m2) 29.0 (6.3)
 Male gender 53% (104)
Race
 White 76% (151)
 Black 19% (37)
 Other 5% (10)
Etiology of CKD
 Diabetes 26% (51)
 Hypertension 53% (104)
 Polycystic kidney disease 7% (14)
 Interstitial renal disease 10% (20)
 Glomerulonephritis 33% (65)
 Other 13% (25)
Coronary risk factors
 Diabetes 30% (59)
 Hypertension 99% (196)
 Current smoker 9% (17)
 Former smoker 40% (80)
 Dyslipidemia 87% (172)
Clinical CVD
 Any clinical CVD 42% (84)
 Cerebrovascular disease 11% (21)
 Coronary artery disease 27% (53)
 Peripheral arterial disease 15% (29)
 Heart failure 19% (37)
Medications
 Diuretic 49% (97)
 Renin-angiotensin-aldosterone system inhibitor 75% (148)
 Beta-adrenergic receptor blocker 51% (100)
 Calcium channel blocker 40% (79)
 Erythropoiesis-stimulating agent 23% (45)
 Statin 48% (94)
 Aspirin 39% (77)
SD = standard deviation.
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Results
Baseline patient characteristics
Demographic and clinical characteristics 
of the study cohort are summarized in Ta-
ble 1. The mean age of the study participants 
was 61 ± 14 years, with a range of 18 – 89 
years. The mean eGFR was 29 ± 12 mL/
min/1.73 m2. Nearly equal numbers had 
stage 3 (n = 86) and stage 4 (n = 88) CKD; 24 
had stage 5 CKD. Diabetes (30%), hyperten-
sion (99%), and CVD (42%) were common 
comorbidities. Laboratory results and indi-
ces of subclinical CVD are shown in Table 2.
Associations of IMT with baseline 
clinical characteristics
The median values for maximum and 
mean IMT were 1.21 (range: 0.48 – 4.91) 
mm, and 0.85 (0.44 – 2.25) mm, respec-
tively. Analyses using maximum and mean 
IMT measurements yielded similar results; 
therefore, only those using maximum IMT 
are described in this manuscript.
The correlations between IMT and eGFR, 
traditional risk factors, novel risk factors and 
other measures of CVD are summarized in 
Table 3. No correlation was observed be-
tween IMT and eGFR. Of traditional cardio-
vascular risk factors, age was most closely 
correlated with IMT; male gender, diabetes, 
current or former tobacco use, dyslipidemia, 
and higher systolic blood pressure (BP) were 
also strongly associated with increased IMT. 
The relationships of diabetes, dyslipidemia, 
and systolic BP with IMT remained signifi-
cant after adjustment for age. Serum albumin 
was the only nontraditional risk factor asso-
ciated with IMT.
Higher values of IMT were significantly 
associated with clinical CVD and with other 
markers of subclinical CVD. Patients with 
a clinical history of coronary artery disease, 
heart failure, cerebrovascular disease, and 
peripheral arterial disease had significantly 
higher values of IMT than those without 
known heart disease, independent of age. Fig-
ure 2 displays the positive correlations of IMT 
with (a) PWV, (b) LVMI, and (c) coronary 
calcification score, as well as (d) the negative 
correlation with heart rate variability (low/
high frequency ratio). These relationships re-
mained statistically significant after correct-
ing for age. There was no significant correla-
tion of IMT with brachial artery FMD.
Table 4 displays results of a multivariable 
model examining traditional risk factors and 
presence of CKD as predictors of maximum 
IMT. Age, diabetes, dyslipidemia, systolic 
BP, and clinical CVD were strong indepen-
dent predictors of carotid IMT.
Association of IMT with clinical 
outcomes
Patients were followed for a median of 
2.4 years following enrollment into the car-
Table 2. Laboratory values and markers of subclinical cardiovascular (CV) 
disease at the time of non-invasive CV testing in the RRI-CKD cohort (n=198).
Mean ± SD or 
median (IQR)
Indices of renal function
 Serum creatinine (mg/dL) 2.3 (1.3)
  Estimated glomerular filtration rate (mL/min/1.73 m2) 29 ± 12
 Blood urea nitrogen (mg/dL) 42.0 ± 20.1
Traditional coronary risk factors
 Total cholesterol (mg/dL) 190 ± 50
 Low-density lipoprotein (mg/dL) 105 ± 39
 High-density lipoprotein (mg/dL) 43 ± 17
 Triglycerides (mg/dL) 148 ± 87
 Systolic blood pressure (mmHg) 137 ± 24
 Diastolic blood pressure (mmHg) 74 ± 14
 Pulse pressure (mmHg) 63 ± 21
 Heart rate (bpm) 65 ± 11
Novel risk factors
 Serum total calcium (mg/dL) 9.2 ± 0.6
 Serum phosphorous (mg/dL) 3.8 ± 0.9
 Serum albumin (mg/dL) 4.0 ± 0.5
 Hematocrit (%) 36.2 ± 4.7
 Intact parathyroid hormone (ng/mL) 117 (148)
 C-reactive protein (mg/L) 2.0 (5.5)
 Urine albumin/creatinine ratio (mg/g) 158 (835)
Markers of subclinical CVD
 Maximum carotid intima-medial thickness† (mm) 1.21 (1.04)
 Mean carotid intima-media thickness† (mm) 0.85 (0.44)
 Flow mediated dilation (%) 3.3 ± 4.2
 Pulse wave velocity (m/s) 9.1 ± 2.9
 Left ventricular mass index (g/m2) 103 (41)
  Coronary calcification score 32 (499)
 Heart rate variability: low/high frequency ratio 2.5 (2.7)
 Heart rate variability: SDNN (ms) 101 (51)
SDNN = standard deviation of all normal R-R (NN) intervals; SD = standard 
deviation; IQR = interquartile range. †Estimated CV (SD/sample mean) for the 
max and mean intima-medial thickness was 0.85/1.46 = 0.59, and 0.37/0.93 = 
0.39, respectively.
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diovascular sub-study. During this time, 47 
patients had at least one CVD event (n = 38) 
and/or died (n = 20), and 45 patients reached 
ESRD.
Maximum IMT ≥ 2.6 mm was associated 
with a composite endpoint of CVD events 
and death (HR: 5.47 (95% CI: 2.97 – 10.07, 
p < 0.0001)) but was not associated with the 
development of end-stage renal disease (HR: 
1.67 (95% CI: 0.74 – 3.76, p = 0.21)). The 
survival curves shown in Figure 3 illustrate 
the higher probability of CVD events or 
death with greater maximum IMT levels. Af-
ter adjustment for age, white race, diabetes, 
and clinical history of CVD, IMT ≥ 2.6 mm 
remained a strong predictor of composite 
endpoint (HR: 2.75 (95% CI: 1.41 – 5.38, 
p = 0.0031)). Maximum IMT also remained 
independently associated with the composite 
endpoint in models that included nontradi-
tional risk factors, FMD, PWV, LVMI, or 
measures of HRV.
Discussion
The principal findings of our study in-
clude the following: 1) patients in our co-
hort with advanced CKD had a high preva-
lence of coronary risk factors and clinical 
CVD; 2) IMT was more closely associated 
with traditional cardiovascular risk fac-
tors, such as age, diabetes, dyslipidemia, 
systolic BP, and tobacco use, than with 
nontraditional risk factors or with eGFR; 
3) higher IMT was associated with clinical 
CVD and with other markers of subclini-
cal disease; and 4) higher IMT predicted 
cardiovascular events, independent of tra-
ditional and nontraditional risk factors and 
prevalent CVD.
Our finding that IMT is more closely 
associated with traditional risk factors than 
with eGFR is consistent with the results from 
several previous population studies [13, 35, 
36]. Studies that have examined factors as-
sociated with carotid atherosclerosis in pa-
tients with advanced, pre-dialysis CKD have 
yielded inconsistent results. Shoji et al. [37], 
measured IMT in 110 non-diabetic pre-dial-
ysis patients with CKD (serum creatinine ≥ 
1.5 mg/dL), 345 non-diabetic patients with 
ESRD treated with maintenance hemodi-
alysis, and 302 healthy controls. IMT was 
similar in patients with CKD and ESRD, and 
Figure 2. Scatter plot and least squares regression line for maximum carotid intima-media thickness 
(IMT) versus (A) pulse wave velocity (PWV), (B) left ventricle mass index, (C) coronary calcification score, 
and (D) heart rate variability (low/high frequency ratio).
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greater than in healthy controls. In the CKD 
group, IMT correlated significantly with age 
and tobacco use, and the relationship with 
systolic BP was of borderline significance; 
there was no correlation of IMT with creati-
nine, total cholesterol, or HDL cholesterol. 
Kawamato et al. [38], examined IMT in 428 
men and 582 women from a single center 
in Japan; 49% had stage 2 CKD, and 32% 
had stage 3 CKD. Age, systolic blood pres-
sure, LDL cholesterol, HDL cholesterol and 
eGFR were significant predictors of IMT in 
both genders, and eGFR was a significant in-
dependent predictor after adjusting for other 
risk factors. In a cohort of Chinese patients 
with stages 3 or 4 CKD, Szeto et al. [39], 
found significant associations of IMT with 
age, LDL-cholesterol, diabetes, and C-reac-
tive protein, but not with systolic BP, ciga-
rette smoking, or kidney function. Lemos et 
al. [40], also noted a significant correlation 
of IMT with C-reactive protein, as well as 
age and systolic BP, but not with eGFR in pa-
tients with predominantly stages 3 or 4 CKD.
Our examination of IMT in the RRI-CKD 
study mirrors the results of our previously 
published analyses from this cohort demon-
strating that changes in arterial compliance 
and coronary calcification are explained by 
conventional CVD risk factors rather than by 
the degree of renal dysfunction or by abnor-
malities in mineral metabolism. Sengstock et 
al. [30], examined PWV in 264 patients from 
the RRI-CKD cohort and 149 subjects with-
out previously recognized CKD. Age, systol-
ic BP, diabetes, body mass index, and heart 
rate were independent predictors of PWV. A 
statistically significant relationship of eGFR 
with PWV was also demonstrated, but eGFR 
explained less than 1% of PWV variability 
in models adjusting for age, systolic BP, dia-
betes, body mass index, and heart rate. Simi-
larly, Dellegrottaglie et al. [31], studied de-
terminants of coronary artery calcium in 106 
patients from the RRI cardiovascular cohort 
who underwent multi-detector computed to-
mography. Coronary artery calcification was 
predicted by age, gender, and diabetes, but 
not by parameters related to renal function, 
including eGFR, calcium, phosphorous, i-
PTH, hemoglobin, and albumin.
Carotid IMT predicts clinical cardio-
vascular events, independent of traditional 
cardiovascular risk factors in the general 
population [21, 22, 23, 24, 25]. In the USE 
intima-media thickness (USE-IMT) global 
meta-analysis project using individual par-
ticipant data from prospective cohort studies 
(n = 45,828), adjusted common carotid IMT 
was positively related to myocardial infarc-
tion and stroke with a hazard ratio per 0.1-
mm difference of common IMT of 1.12 (95% 
Table 3. Pearson correlations of maximum carotid intima-media thickness 
(IMT; natural log-scale) with traditional and nontraditional risk factors and bio-
markers of cardiovascular risk (n = 198).
Pearson r p-value
Demographic/anthropomorphic measures
 Age (years) 0.61 < 0.001
 Male gender 0.14 0.044
 Black race –0.09 0.213
 Body mass index (kg/m2) 0.05 0.445
Indices of renal function
 Serum creatinine (mg/dL)† –0.02 0.829
  Estimated glomerular filtration rate (mL/min/1.73 m2) –0.04 0.541
 Blood urea nitrogen (mg/dL) 0.19 0.008
Clinical CVD
 Any clinical CVD 0.42 < 0.001
 Cerebrovascular disease 0.16 0.020
 Coronary artery disease 0.36 < 0.001
 Peripheral arterial disease 0.25 < 0.001
 Heart failure 0.35 < 0.001
Traditional coronary risk factors
 Diabetes 0.32 < 0.001
 Hypertension 0.04 0.564
 Current or former smoker 0.19 0.009
 Dyslipidemia 0.20 0.006
 Total cholesterol (mg/dL) –0.13 0.084
 Low-density lipoprotein (mg/dL) –0.14 0.053
 High-density lipoprotein (mg/dL) –0.01 0.901
 Triglycerides (mg/dL) 0.01 0.895
 Systolic blood pressure (mmHg) 0.32 < 0.001
 Pulse pressure (mmHg) 0.43 < 0.001
 Heart rate (bpm) –0.01 0.903
Novel coronary risk factors
 Serum total calcium (mg/dL) 0.00 0.967
 Serum phosphorous (mg/dL) 0.05 0.517
 Serum albumin (mg/dL) –0.18 0.013
 Hematocrit (%) –0.10 0.169
 Intact parathyroid hormone (ng/mL)† 0.00 0.980
 C-reactive protein (mg/L)† 0.11 0.126
 Urine albumin/creatinine ratio (mg/g)† 0.03 0.683
Markers of subclinical CVD
 Flow-mediated dilation (%) –0.06 0.397
 Pulse wave velocity (m/s) 0.46 < 0.001
 Left ventricular mass index (g/m2)† 0.36 < 0.001
  Coronary calcification score† 0.46 < 0.001
 Heart rate variability: low/high frequency ratio† –0.30 < 0.001
 Heart rate variability: SDNN (ms)† 0.00 0.979
SDNN = standard deviation of all normal R-R (NN) intervals; †Natural log-scale.
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CI 1.09 – 1.14) for women and 1.08 (95% CI 
1.05 – 1.11) for men [26]. Increased IMT is 
also associated with adverse outcomes in di-
alysis patients [41, 42] and was a predictor 
of fatal and nonfatal cardiovascular events 
in subjects with stages 4 to 5 CKD enrolled 
in the atherosclerosis and folic acid supple-
mentation trial [43]. The associations of IMT 
with prevalent CVD and with CVD events 
in patients with advanced pre-dialysis CKD 
have not been extensively studied. Adesun et 
al. [44], demonstrated that IMT was a predic-
tor of self-reported CVD, with a c-statistic 
of 0.64, in an ancillary study of the chronic 
renal insufficiency cohort (CRIC) study. Sze-
to et al. [39] followed 203 Chinese patients 
with stage 3 or 4 CKD for an average of 52 
months. As noted in our cohort, IMT was an 
independent predictor of survival free from 
cardiovascular events, but not of progression 
to ESRD. Our study extends the findings of 
Szeto et al. [39], by demonstrating in a mul-
tiracial cohort an association of IMT with 
cardiovascular events that is independent of 
traditional CVD risk factors.
Previous studies of atherosclerosis in 
population-based cohorts have emphasized 
the prognostic importance of carotid plaque 
[21, 45]. Our analysis of outcomes using 
maximum IMT suggests that plaque is also 
a powerful predictor of adverse outcomes in 
patients with CKD. Mean of maximum IMT 
was calculated from the maximum intima-
media thickness of each imaged segment, 
which reflects the maximum height of any 
plaque in that segment. Thus, high values 
for maximum IMT suggest the presence of 
plaque. A marked increase in mean maxi-
mum IMT (≥ 2.6 mm) was associated with 
more than a five-fold increase in the risk of 
cardiovascular events in our cohort, and re-
mained significantly associated with poor 
outcomes after adjustment for CVD and oth-
er risk factors.
Our study has limitations which are im-
portant to consider when interpreting the re-
sults. The absence of a clear association of 
IMT with eGFR may be in part due to the 
narrow range of values for eGFR in our sub-
jects. It may also reflect a survival bias in 
this referred cohort of CKD patients; patients 
with more extensive atherosclerosis (and 
greater IMT) may have died before reach-
ing advanced stages of CKD. Treatment with 
medications may also obscure relationships 
between risk factors and IMT. The majority 
of our subjects were prescribed anti-hyper-
tensive agents, and nearly half were treated 
with a statin. Our cross-sectional analyses do 
not take into account the duration of expo-
sure to risk factors. Although carotid IMT is 
independently associated with a risk of car-
diovascular events, it is an imperfect mea-
sure of atherosclerosis and may not neces-
sarily reflect disease in other vascular beds. 
Finally, creatinine was measured in different 
laboratories (at the individual sites) and GFR 
was estimated, not measured.
We conclude that carotid IMT reflects 
clinical and subclinical CVD in patients with 
Figure 3. The cumulative probabilities of CVD 
events or death over time by maximum carotid 
intima-media thickness (IMT) above and below 2.6 
mm are displayed. Martingale residuals obtained 
from Cox regression models were examined to as-
sess the correct functional form of IMT (i.e., non-
linear). Maximum  IMT  ≥  2.6 mm was  associated 
with a higher risk of CVD events or death, com-
pared to patients with maximum carotid IMT < 2.6. 
Plotted values were calculated based on Cox re-
gression adjusted for mean age (61), proportion of 
whites (0.76), proportion with diabetes (0.30), and 
history of CVD (0.42).
Table 4. Multiple linear regression model predicting maximum carotid intima-
media thickness (natural log-scale). Parameter estimates (β) and p-values are 
displayed (model R2 = 0.51, n = 198).
Variable β p-value
Age, per 10 years 0.20 < 0.001
White race 0.11 0.099
Diabetes 0.19 0.003
Dyslipidemia 0.24 0.005
Presence of clinical CVD 0.18 0.004
Systolic blood pressure, per 10 mmHg 0.03 0.005
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advanced pre-dialysis CKD and is associated 
with traditional cardiovascular risk factors, 
especially older age, hypertension, diabe-
tes and dyslipidemia. IMT is a predictor of 
adverse cardiovascular events independent 
of traditional and novel risk factors in this 
population. Additional research is needed to 
examine the clinical utility of IMT in the risk 
stratification and clinical management of pa-
tients with CKD.
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